Figure S1a-S8 from Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study

Résumé fourni par la source

Figures S1a: Response rates at serial time points in evaluable patients. Histogram showing iwCLL 2018 response at serial study time points in evaluable patients. CR/CRi rate was 64% at the end of cycle 12 and 77% at the end of cycle 24 of combination therapy. The best CR/CRi rate was 71% at anytime during the study treatment Figure S1b: Marrow UMRD4 rates in evaluable patients. Histogram showing bone marrow UMRD4 rates at serial study time points in evaluable patients. Bone marrow UMRD4 rate was 48% at the end of cycle 12 and 71% at the end of cycle 24 of combination therapy. The best bone marrow UMRD4 rate was 64% at anytime during the study treatment. Figure S2: Time to First Bone Marrow UMRD4. Reversed Kaplan-Meier survival estimate curve for time to first bone marrow UMRD4. The analysis included all patients who had MRD assessments after 3 months of combination therapy. Figure S3: Progression-free survival and overall survival stratified by IGHV mutation status (n=76). Kaplan-Meier progression-free and overall survival estimate curves stratified by IGHV mutation status. Log-rank test was used to compare between IGHV mutated and unmutated subgroups. Figure S4: Progression-free survival and overall survival in stratified by prior chemoimmunotherapy treatment. Kaplan-Meier progression-free and overall survival estimate curves stratified by prior chemoimmunotherapy treatment status. Log-rank test was used to compare between the two subgroups. Figure S5a: Time to treatment discontinuation in all patients. Kaplan-Meier survival estimate curve for time to treatment discontinuation. Figure S5b: Time to treatment discontinuation, stratified by IGHV status. Kaplan-Meier survival estimate curve for time to treatment discontinuation stratified by IGHV mutation status. Log-rank test was used to compare between the two subgroups. Figure S5c: Time to treatment discontinuation, stratified by TP53 aberration. Kaplan-Meier survival estimate curve for time to treatment discontinuation stratified by TP53 aberration status. Log-rank test was used to compare between the two subgroups. Figure S5d: Time to treatment discontinuation, stratified by prior chemoimmunotherapy treatment. Kaplan-Meier survival estimate curve for time to treatment discontinuation stratified by prior chemoimmunotherapy treatment status. Log-rank test was used to compare between the two subgroups. Figure S6: Patient Disposition. Flowchart showing patient disposition. Figure S7: Time to MRD recurrence in peripheral blood. Reversed Kaplan-Meier survival estimate curve for time to MRD recurrence in peripheral blood. Figure S8: Time to next treatment. Kaplan-Meier survival estimate curve for time to next treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.